Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab single-arm phase II study in advanced previously treated ovarian cancer
ChiCTR2000041447Phase 4Recruiting
- Sponsor
- Anqing Municipal Hospital
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in ovarian cancer, sponsored by Anqing Municipal Hospital. Primary endpoint: Progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000041447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041447.